Highlights ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 18:16:11 16/07/2025 BST			5-day change	1st Jan Change
2.745 ^USD	+0.18%		-0.72%	+8.20%

07-08	Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday Amid Tariff Pause	MT
07-08	ImmunityBio Granted UK Approval for Bladder Cancer Treatment	MT

Highlights

UK MHRA Approves ImmunityBio?s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ	07-08	CI
UK Regulator OKs ImmunityBio's Bladder Cancer Treatment for New Indication	07-04	MT
ImmunityBio Receives Expanded FDA Authorization to Treat Lymphopenia in Cancer Patients	06-02	MT
Immunitybio, Inc. Receives Fda Expanded Access Authorization for Landmark Treatment of Lymphopenia with Anktiva, the Cancer Bioshield? Platform, in Patients with Solid Tumors	06-02	CI
Immunitybio Receives FDA Expanded Access Authorization For Landmark Treatment Of Lymphopenia With Anktiva	06-02	RE
ImmunityBio Signs Agreement to Launch BioShield in Saudi Arabia, Middle East	05-27	MT
Immunitybio, Inc. Signs Strategic Memorandum of Understanding to Launch Cancer Bioshield Platform in the Middle East	05-27	CI
Immunitybio Q1 Revenue USD 16.517 Million	05-12	RE
ImmunityBio Q1 Loss Narrows, Revenue Rises	05-12	MT
Earnings Flash (IBRX) ImmunityBio Posts Q1 Net Loss $0.15 a Share, vs. FactSet Est of $0.13 Loss	05-12	MT
Earnings Flash (IBRX) IMMUNITYBIO INC. Reports Q1 Revenue $16.5M, vs. FactSet Est of $16.0M	05-12	MT
ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-12	CI
ImmunityBio, Inc. Receives Refusal to File Letter from the U.S. Food and Drug Administration for the Supplemental Biologics License Application	05-05	CI
ImmunityBio Requests An Urgent Meeting With FDA To Address The Change In The Agency'S Unambiguous Guidance On Jan 2025 To Submit A SBLA For NMIBC BCG Unresponsive Papillary Disease, Following An Inconsistent Refusal To File Letter On May 2, 2025	05-05	RE
ImmunityBio, Inc. Announces Positive Long-Term Results from Its Quilt-3.032 Study of Anktiva® (Nogapendekin Alfa Inbakicept-Guerin) Plus BCG	04-28	CI
Immunitybio Announces FDA Submissions Of Supplemental BLA For Nmibc Papillary Disease And For Expanded Access Of Anktiva®To Treat Lymphopenia	04-15	RE
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA to Treat Lymphopenia	04-15	CI
ImmunityBio, Inc. Announces First Dosing of Recombinant BCG in the U.S. and 60 Sites Are in the Process of Launching	03-13	CI
ImmunityBio's Q4 Net Loss Narrows, Revenue Rises	03-03	MT
ImmunityBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	03-03	CI
Earnings Flash (IBRX) ImmunityBio Posts Q4 Net Loss $-0.09 a Share, vs. FactSet Est of $-0.20 Loss	03-03	MT
Earnings Flash (IBRX) IMMUNITYBIO INC. Posts Q4 Revenue $7.6M, vs. FactSet Est of $9.6M	03-03	MT
ImmunityBio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	03-03	CI
ImmunityBio, Inc. Announces Certain Operational Results Following Approval of the Permanent J-Code in January 2025	03-03	CI
ImmunityBio, Inc. Receives FDA RMAT Designation for ANKTIVA and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-Of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer	02-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Biotechnology & Medical Research

Highlights

Filters